Zydus Lifesciences shares in focus as firm acquires US-based Assertio Holdings for $166 million

Zydus Lifesciences has completed its acquisition of US-based Assertio Holdings for about $166 million (around $23.50 per share in cash) through its wholly-owned subsidiary Zara Merger Sub Inc. Assertio, which specialises in speciality and oncology supportive-care therapies, has become a wholly-owned subsidiary and its shares have been delisted from the Nasdaq Global Market. The acquisition strengthens Zydus's innovative drug pipeline and US footprint, with the company holding a market capitalisation of about Rs 1.09 lakh crore.